SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by von Beckerath, N. Articles by Kastrati, A. Search for Related Content PubMed PubMed Citation Articles by von Beckerath, N. Articles by Kastrati, A. Related Collections Hemostasis, Thrombosis, and Vascular Biology Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 95 No. 11 (June 1), 2000: pp. 3297-3301 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting Nicolas von Beckerath, Werner Koch, Julinda Mehilli, Corinna Böttiger, Albert Schömig, and Adnan Kastrati From Deutsches Herzzentrum and 1. Medizinische Klinik rechts der Isar, Technische Universität München, Munich, Germany.     Abstract Top Abstract Introduction Patients and methods Results Discussion References The glycoprotein complex Ia/IIa (GP Ia/IIa) is a major collagen receptor on platelets and other cell types. Recently, linked polymorphisms within the coding region of the GP Ia gene (C807T and G873A) were identified that are related to GP Ia/IIa surface expression. The T807/A873 allele is associated with high expression, whereas the C807/G873 allele is associated with low surface expression of GP Ia/IIa. Subsequently, the T807 allele was found to be associated with coronary and cerebral infarction in younger patients. Platelet adhesion to the vessel wall plays a pivotal role in thrombosis after coronary artery stent placement. The goal of this study was to test whether C807T polymorphism is associated with a higher incidence of thrombotic events following coronary stenting. Consecutive patients treated with coronary stent placement (n = 1797) were genotyped for C807T polymorphism with polymerase chain reaction and allele-specific fluorogenic probes. The composite end point was defined as death, myocardial infarction, or urgent target vessel revascularization within 30 days of stent implantation. The genotype distribution of the study population was CC in 36.5%, CT in 46.7%, and TT in 16.8% of the patients. The incidence of the composite end point was 6.5% in T allele carriers and 5.3% in noncarriers (odds ratio for T allele carriage 1.23 [95% confidence interval, 0.81-1.86], P = .33). After adjusting for other baseline characteristics, the odds ratio for the composite end point was 1.15 (0.76-1.75). Therefore, C807T genotype has no significant influence on the major adverse events occurring after coronary artery stenting. (Blood. 2000;95:3297-3301) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Patients and methods Results Discussion References The integrin 21 (also known as glycoprotein Ia/IIa [GP Ia/IIa] or very late antigen 2 [VLA-2]) is a major platelet collagen receptor. GP Ia/IIa binding to subendothelial collagens plays an important role in platelet adhesion and activation following initial platelet vessel wall interaction mediated by von Willebrand factor.1,2 Deficiency of GP Ia3-5 or the presence of inhibitory antibodies directed against the GP Ia/IIa complex6 results in impaired hemostasis and a bleeding disorder of variable extent. Kunicki et al7 found a 3- to 4-fold interindividual variation of GP Ia/IIa surface expression. A corresponding variation was observed for 2- but not for 1-subunit expression.7 In contrast, surface expression of other platelet membrane receptors like IIb 3, 5 1, and GP IV shows little interindividual variation.7,8 Recently, 2 silent, linked polymorphisms (C807T and G873A) within the coding region of the 2 gene have been identified that are associated with the number of GP Ia/IIa copies on the platelet membrane.9 Other polymorphisms of the 2 gene such as Br10 are also linked with C807T polymorphism.11 High GP Ia/IIa surface expression was found in platelets derived from T807 homozygotes, whereas low surface expression was found in platelets from C807 homozygotes.8,9,12 Because the number of GP Ia/IIa receptors on the platelet surface correlates with platelet adhesion to collagens,7,11 T807 may be associated with thrombosis. Several recent studies have investigated the possible association between C807T genotype and the incidence of thrombotic, ischemic events in a clinical setting.12-16 In a large consecutive series of patients including 1050 survivors of myocardial infarction and 1187 controls, an association between T allele and myocardial infarction was found in younger patients.14 Specifically, for patients less than 62 years old, the odds ratio (OR) for T807 carriers versus noncarriers was 1.57 (1.14-2.13) and for patients less than age 49 years, the respective OR was 2.61(1.26-5.41). In a smaller study, a similar age-dependent association was also found for stroke patients, with an OR of 3.02 (1.20-7.61) for T allele carriers less than age 50 years.15 Moshfegh et al13 found a strong, age-independent association between T807 homozygosity and myocardial infarction. Two recent studies, however, found no association between C807T genotype and thrombotic diseases12 or myocardial infarction,16 showing that the clinical significance of this polymorphism is still not completely clarified. Therefore, further study of the role of C807T polymorphism in other thromboembolic disease states related to platelet-collagen interaction has recently been recommended.2 Stent placement in coronary arteries is now the most common interventional treatment for symptomatic coronary artery disease. Compared to plain angioplasty (percutaneous transluminal coronary angioplasty), stenting allows for a higher primary success rate17,18 and a reduced restenosis rate.19,20 Early thrombotic events remain, however, a serious problem of coronary stenting.21 The placement of coronary stents induces marked platelet activation.22 Moreover, animal studies have shown that, besides the interaction of the stent surface with the flowing blood, the extent of vessel wall injury has an influence on the formation of stent thrombosis.23,24 Because collagens are major components of the subendothelial matrix, differential expression of GP Ia/IIa may have an effect on platelet adhesion and activation after coronary stent placement. This study was designed to test whether the C807T polymorphism, which is associated with elevated GPIa/IIa surface expression, results in an increased risk of adverse thrombotic events following coronary artery stenting.     Patients and methods Top Abstract Introduction Patients and methods Results Discussion References Patients This study included all patients with stable or unstable angina pectoris who underwent a stent implantation procedure in the period from April 1996 through January 1998. The patients who underwent coronary stenting in the setting of acute myocardial infarction were excluded from the study. Implantation of various slotted-tube stents was performed as previously described.18,25 More than 95% of the stents were hand-crimped on conventional angioplasty balloons and delivered under fluoroscopic guidance. Therapy after the procedure consisted of aspirin (100 mg twice daily, indefinitely) and ticlopidine (250 mg twice daily for 4 weeks; Tiklyd, Sanofi-Winthrop, Munich, Germany). Patients with angiographic appearance of thrombus on the stented site received additional therapy with abciximab (Lilly Deutschland GmbH, Giessen, Germany) given as bolus injection during the stent insertion procedure and as a 12-hour continuous infusion thereafter. The decision to give abciximab was left to operator's discretion. Patients with symptoms or signs of recurrent ischemia after the intervention underwent repeat angiography. Genotyping Genomic DNA was extracted from 200 µL peripheral blood leukocytes with the QIAamp Blood Kit (Qiagen, Hilden, Germany) or the High Pure PCR Template Preparation Kit (Boehringer Mannheim, Mannheim, Germany). Genotyping of the 2 C807T polymorphism was performed with the ABI Prism Sequence Detection System (PE Applied Biosystems, Weiterstadt, Germany). The use of allele-specific fluorogenic probes in the 5' nuclease reaction combines DNA amplification and genotype determination into a single assay.26 The nucleotide sequences of primers and probes were as follows: forward primer 5' CAT CCC AGA CAT CCC AAT ATG G 3', reverse primer 5' GGC CTA TTA GCA CCA AAA CTT ACC TT 3', allele C807 probe 5' CCT CAC AAA CAC ATT CGG AGC AAT 3', allele T807 probe 5' ACC TCA CAA ACA CAT TTG GAG CAA TTC AA 3'. Allele C807 probe was labeled with the fluorescent dye: 6-carboxy-fluorescein (FAM) and allele T807 probe was labeled with VIC (PE Applied Biosystems, patent pending) at their 5' ends. The probes were labeled with the quencher 6-carboxy-tetramethyl-rhodamine (TAMRA) at their 3' ends. The thermocycling protocol consisted of 40 cycles of denaturation at 95°C for 15 seconds and annealing/extension at 62°C for 1 minute. The 2 Br genotypes were determined by allele-specific restriction enzyme analysis, as previously described.27 Primers 5' GTG ACC TAA AGA AAG AGG 3' and 5' CTC TCA TGG AAA ATG GCA G 3' were used to amplify a 274-bp sequence containing the Br polymorphic site. Polymerase chain reaction (PCR) products were digested with MnlI. Restriction fragments were separated by electrophoresis in 8% polyacrylamide gels (Novex, Frankfurt/Main, Germany) and, after staining with ethidium bromide solution, identified by 312-nm UV transillumination. Angiographic assessment Lesions were classified according to the modified American College of Cardiology/American Heart Association grading system.28 Type B2 and C lesions were considered complex lesions. The diagnosis of reduced left ventricular function was established in the presence of at least 2 hypokinetic segments in the contrast angiogram. The diagnosis of stent closure was established angiographically in the presence of a flow of grade 0 or 1 according to the Thrombolysis in Myocardial Infarction (TIMI) trial.29 The quantitative analysis was performed off-line for angiograms before and immediately after stent placement using the automated edge-detection system CMS (Medis Medical Imaging Systems, Nuenen, The Netherlands) and computing the following parameters: minimal lumen diameter, reference diameter, percent diameter stenosis, and diameter of the maximally inflated balloon. Definitions and end point of the study Procedural failure was defined as failure to place the stent at the desired position or to achieve a final diameter stenosis of less than 30% by visual inspection. The end point of adverse events within the first 30 days after the procedure was a combination of death from any cause, myocardial infarction, and severe myocardial ischemia requiring urgent revascularization by means of coronary bypass surgery or percutaneous intervention. Myocardial infarction was defined as new abnormal Q waves on the electrocardiogram (Q-wave myocardial infarction) or a value of creatine kinase or its MB isoenzyme at least 3 times the upper limit of normal (non-Q-wave infarction). Cardiac enzymes were systematically determined after the intervention. Assuming that about 70% of patients are T807 carriers, the sample size in our study was estimated to provide 80% power for detecting an increase in the risk for adverse events from 6% in CC patients to 10% in those who carry the T allele. Statistical analysis Discrete variables are expressed as counts and compared with 2 or Fisher exact test as appropriate. The Hardy-Weinberg equilibrium was tested according to Guo et al.30 Continuous variables are expressed as mean ± SD and compared by means of the unpaired, 2-sided t test. The possible association between the presence of the T807 allele and adverse events was also assessed after adjusting for other factors using multiple logistic regression analysis. Together with the genotype, all factors resulting with a P value less than .2 in the univariate analysis were entered into the multivariate model as potential confounding factors. The risk associated with each factor was assessed on the basis of the respective OR and the corresponding 95% confidence interval (CI). All statistical analyses were performed using S-Plus software (Mathsoft, Seattle, WA). Statistical significance was assumed for P values less than .05.     Results Top Abstract Introduction Patients and methods Results Discussion References The study included 1797 patients. C807T genotype distribution was CC in 36.5%, CT in 46.7%, and TT in 16.8% of the patients. Br genotype was a/a in 0.7%, a/b in 18.2%, and b/b in 81.1% of the patients. The distributions of both genotypes fit the Hardy-Weinberg equilibrium. The relation between C807T and Br polymorphisms is displayed in Table 1. Table 2 shows the baseline characteristics of the patients according to their C807T genotype. TT patients were significantly older and more likely to have diabetes and reduced left ventricular function. Table 3 shows comparable angiographic and procedural characteristics for CC, CT, and TT patients. The proportion of patients with successful procedures was similar among the 3 genotypes.                                View this table: [in this window] [in a new window]   Table 1. Relation between C807T and Br polymorphisms in the 1797 study patients                                View this table: [in this window] [in a new window]   Table 2. Baseline clinical characteristics of the patients according to the C807T genotype                                View this table: [in this window] [in a new window]   Table 3. Lesion and procedural characteristics at the time of intervention according to the C807T genotype Table 4 displays the adverse events within 30 days of coronary artery stenting according to C807T genotype. No significant differences were found for any of the events and for the composite end point of the study. The incidence of adverse major events was 6.5% in T allele carriers and 5.3% in noncarriers (OR for T allele carriage, 1.23 [95% CI, 0.81-1.86], P = .33). The events occurred overwhelmingly during the first 4 days after stenting (83%); even during this period there was no significant difference in the incidence of adverse events: 4.7% in CC, 5.7% in CT, and 4.7% in TT patients (P = .66). In addition, subacute stent thrombosis was observed in 10 (1.6%) CC, 16 (2.0%) CT, and 6 (2.0%) TT patients (P = .31). Table 5 displays the adverse events within 30 days of coronary artery stenting according to Br genotype. Here also there was no significant difference among the different genotypes.                                View this table: [in this window] [in a new window]   Table 4. Major adverse events during the first 30 days after stent placement according to C807T genotype                                View this table: [in this window] [in a new window]   Table 5. Major adverse events during the first 30 days after stent placement according to the Br genotype Table 6 shows the results of the different subgroup analyses. The lack of association between C807T genotype and early outcome after stenting was independent of the procedural success, administration of abciximab, and age. Of the 38 patients with procedural failure, 13 (34.2%) incurred an early major adverse event without significant differences among the 3 genotypes: 29.4% in CC, 41.2% in CT, and 25.0% in TT patients (P = .71).                                View this table: [in this window] [in a new window]   Table 6. Major adverse events during the first 30 days after stent placement in different subsets of patients according to the C807T genotype A multivariate model for the composite end point was constructed and age, diabetes, unstable angina, reduced left ventricular function, a history of bypass surgery, multivessel disease, and number of stents implanted (all factors with a P < .2 in the univariate analysis) as well as C807T genotype were entered as potential independent predictors. The adjusted OR for T allele homozygosity versus C allele homozygosity was 1.04 (0.60-1.82) and for T allele carriage 1.15 (0.76-1.75). The multivariate analysis revealed no interaction between the C807T genotype and other factors with respect to the occurrence of adverse events.     Discussion Top Abstract Introduction Patients and methods Results Discussion References The main result of this study is that the T807 allele of the GP Ia gene is not associated with an increased risk of major adverse events following coronary artery stenting. This result was obtained in a large consecutive series of patients who were carefully monitored for the occurrence of adverse thrombotic events. Most thrombotic events occur during the first days following stent implantation.21 Serial determination of creatine kinase and its myocardial isoenzyme allowed registration of postprocedural thrombotic events causing non-Q-wave infarction. Such events are often caused by embolization of platelet aggregates into more distal vessels or side branch occlusions31 as opposed to the less frequent complete thrombotic occlusion of the stented artery. Therefore, the composite end point of this study allowed an extensive evaluation of postprocedural thrombosis as a prerequisite to investigate a prothrombotic genetic factor in this specific setting. In our study group, the T allele frequency was 0.40, which is identical to the value reported for the group of patients studied by Santoso et al14 and slightly higher than the T allele frequency found in healthy blood donors.12 We also genotyped the patient population for the GP Ia Br polymorphism and found no correlation with early outcome after stenting. So far, as in the case of our study, Bra has only been found in homozygous or heterozygous C allele carriers.8,11 Moreover, Bra is rarely encountered in whites,32-34 with an allele frequency of around 0.1, which corresponds to the frequency found also in the present study, and platelet adhesiveness to collagens was not dependent on Br polymorphism.10 The number of GP Ia/IIa copies exposed on the surface of a single platelet, as assessed by radioactive ligand binding, has been reported to be in the range of 1000 to 3000.7 With flow cytometry, surface expression of GP Ia/IIa receptors was found to be twice as high in T807 homozygotes as compared with C807 homozygotes.8,9 In heterozygotes, mean fluorescence of the fluorogenic antibodies directed either against GP Ia or the GP Ia/IIa complex was in between the values for C807 and T807 homozygotes.8,9 In 1 family, the number of GP Ia/IIa receptors was quantified with radioactive ligand binding assay and the mean values obtained were 2325 for the TT father, 933 for the CC mother, and 1612 and 1606 for the CT sons.9 Moreover, direct evidence indicates that C807T-related variation of GP Ia/IIa surface expression affects platelet-collagen interaction. First, in a flow chamber, C807T genotype was associated with the rate of platelet attachment to collagen I at high shear.11 Second, in patients with a moderate deficiency of von Willebrand factor, the T807 allele was associated with longer closure times in a high shear stress system that simulates platelet-based hemostasis in vitro.35 Coronary artery stent placement causes marked platelet activation as has been shown experimentally and in clinical trials.22,25,36-38 Following stent implantation, surface expression of the activated fibrinogen receptor and P-selectin increase and, concomitantly, platelet count and plasma fibrinogen concentration decrease.22,39 Differences between stent-induced thrombosis and spontaneous coronary thrombosis may underlie the lack of an association between C807T genotype and the incidence of early adverse events following coronary artery stenting. Spontaneous coronary thrombosis is a result of platelet adhesion, activation, and aggregation following rupture or erosion of an atherosclerotic plaque,40,41 which often causes only a mild or moderate coronary stenosis.42 Tissue factor is particularly abundant in the lipid core of these plaques and is exposed to the flowing blood after plaque disruption.43 Therefore, tissue factor-induced thrombin generation may play an important role in platelet activation on the plaque surface. Accordingly, in perfused human arterial segments, addition of tissue factor pathway inhibitor resulted in a decrease of platelet and fibrinogen deposition on disrupted atherosclerotic plaques.44 In contrast, high-grade coronary lesions that are treated with stent placement are usually caused by collagen-rich fibrotic plaques that contain less tissue factor.43,45 Exposure of the thrombogenic device itself may play a significant role in marked platelet activation that follows coronary stent placement.37,46 Thus, the mode of platelet activation may differ in both types of arterial thrombosis. This may influence the function of GP Ia/IIa and the relative importance of this adhesion molecule.     Footnotes Submitted August 2, 1999; accepted January 5, 2000. Reprints: Nicolas von Beckerath, Deutsches Herzzentrum München, Lazarettstr. 36, 80636 Munich, Germany; e-mail: beckerath{at}dhm.mhn.de. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.     References Top Abstract Introduction Patients and methods Results Discussion References 1. Verkleij MW, Morton LF, Knight CG, de Groot PG, Barnes MJ, Sixma JJ. Simple collagen-like peptides support platelet adhesion under static but not under flow conditions: interaction via alpha2 beta1 and von Willebrand factor with specific sequences in native collagen is a requirement to resist shear forces. Blood. 1998;91:3808[Abstract/Free Full Text]. 2. Santoro SA. Platelet surface collagen receptor polymorphisms: variable receptor expression and thrombotic/hemorrhagic risk. Blood. 1999;93:3575[Free Full Text]. 3. Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature. 1985;318:470[Medline] [Order article via Infotrieve]. 4. Kehrel B, Balleisen L, Kokott R, et al. Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood. 1988;71:1074[Abstract/Free Full Text]. 5. Handa M, Watanabe K, Kawai Y, et al. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder. Thromb Haemost. 1995;73:521[Medline] [Order article via Infotrieve]. 6. Deckmyn H, Chew SL, Vermylen J. Lack of platelet response to collagen associated with an autoantibody against glycoprotein Ia: a novel cause of acquired qualitative platelet dysfunction. Thromb Haemost. 1990;64:74[Medline] [Order article via Infotrieve]. 7. Kunicki TJ, Orchekowski R, Annis D, Honda Y. Variability of integrin alpha 2 beta 1 activity on human platelets. Blood. 1993;82:2693[Abstract/Free Full Text]. 8. Corral J, Rivera J, Gonzalez-Conejero R, Vicente V. The number of platelet glycoprotein Ia molecules is associated with the genetically linked 807 C/T and HPA-5 polymorphisms. Transfusion. 1999;39:372[Medline] [Order article via Infotrieve]. 9. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood. 1997;89:1939[Abstract/Free Full Text]. 10. Santoso S, Kalb R, Walka M, Kiefel V, Mueller-Eckhardt C, Newman PJ. The human platelet alloantigens Br(a) and Br(b) are associated with a single amino acid polymorphism on glycoprotein Ia (integrin subunit 2). J Clin Invest. 1993;92:2427. 11. Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood. 1998;92:2382[Abstract/Free Full Text]. 12. Corral J, Gonzalez-Conejero R, Rivera J, Ortuno F, Aparicio P, Vicente V. Role of the 807 C/T polymorphism of the alpha2 gene in platelet GP Ia collagen receptor expression and function: effect in thromboembolic diseases. Thromb Haemost. 1999;81:951[Medline] [Order article via Infotrieve]. 13. Moshfegh K, Wuillemin WA, Redondo M, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet. 1999;353:351[Medline] [Order article via Infotrieve]. 14. Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood. 1999;93:2449[Abstract/Free Full Text]. 15. Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integrin alpha2beta1 might be a genetic risk factor for the development of stroke in younger patients. Blood. 1999;93:3583[Abstract/Free Full Text]. 16. Croft SA, Hampton KK, Sorrell JA, et al. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction [in process citation]. Br J Haematol. 1999;106:771[Medline] [Order article via Infotrieve]. 17. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316:701[Abstract]. 18. Schomig A, Kastrati A, Mudra H, et al. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation. 1994;90:2716[Abstract/Free Full Text]. 19. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489[Abstract/Free Full Text]. 20. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496[Abstract/Free Full Text]. 21. Schuhlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation. 1998;98:104[Abstract/Free Full Text]. 22. Gawaz M, Neumann FJ, Ott I, May A, Rudiger S, Schomig A. Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart. 1996;76:166[Abstract/Free Full Text]. 23. Sheth S, Litvack F, Dev V, Fishbein MC, Forrester JS, Eigler N. Subacute thrombosis and vascular injury resulting from slotted-tube nitinol and stainless steel stents in a rabbit carotid artery model. Circulation. 1996;94:1733[Abstract/Free Full Text]. 24. Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation. 1995;91:2995[Abstract/Free Full Text]. 25. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med. 1996;334:1084[Abstract/Free Full Text]. 26. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal. 1999;14:143[Medline] [Order article via Infotrieve]. 27. Kalb R, Santoso S, Unkelbach K, Kiefel V, Mueller-Eckhardt C. Localization of the Br polymorphism on a 144 bp exon of the GPIa gene and its application in platelet DNA typing. Thromb Haemost. 1994;71:651[Medline] [Order article via Infotrieve]. 28. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation. 1990;82:1193[Abstract/Free Full Text]. 29. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. N Engl J Med. 1985;312:932[Medline] [Order article via Infotrieve] 30. Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics. 1992;48:361[Medline] [Order article via Infotrieve]. 31. Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J. 1996;131:1097[Medline] [Order article via Infotrieve]. 32. Kiefel V, Santoso S, Katzmann B, Mueller-Eckhardt C. The Bra/Brb alloantigen system on human platelets. Blood. 1989;73:2219[Abstract/Free Full Text]. 33. Holensteiner A, Walchshofer S, Adler A, Kittl EM, Mayr WR, Panzer S. Human platelet antigen gene frequencies in the Austrian population. Haemostasis. 1995;25:133[Medline] [Order article via Infotrieve]. 34. Unkelbach K, Kalb R, Santoso S, Kroll H, Mueller-Eckhardt C, Kiefel V. Genomic RFLP typing of human platelet alloantigens Ww(PlA), Ko, Bak and Br (HPA-1, 2, 3, 5). Br J Haematol. 1995;89:169[Medline] [Order article via Infotrieve]. 35. Di Paola J, Federici AB, Mannucci PM, et al. Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood. 1999;93:3578[Abstract/Free Full Text]. 36. Neumann FJ, Gawaz M, Ott I, May A, Mossmer G, Schomig A. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol. 1996;27:15[Abstract]. 37. Gutensohn K, Beythien C, Bau J, Meinertz T, Kuehnl P. Flow cytometric analysis of coronary stent-induced alterations of platelet antigens in an in vitro model. Thromb Res. 1997;86:49[Medline] [Order article via Infotrieve]. 38. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87[Medline] [Order article via Infotrieve]. 39. Gawaz M, Neumann FJ, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation. 1999;99:E1. 40. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997;336:1276[Abstract/Free Full Text]. 41. Gutstein DE, Fuster V. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res. 1999;41:323[Abstract/Free Full Text]. 42. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657[Free Full Text]. 43. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594[Abstract/Free Full Text]. 44. Badimon JJ, Lettino M, Toschi V, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation. 1999;99:1780[Abstract/Free Full Text]. 45. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126[Abstract/Free Full Text]. 46. Beythien C, Gutensohn K, Bau J, et al. Influence of stent length and heparin coating on platelet activation: a flow cytometric analysis in a pulsed floating model. Thromb Res. 1999;94:79[Medline] [Order article via Infotrieve]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: The platelet glycoprotein Ia C807T polymorphism as risk factor for coronary catheter interventions Christian Meisel, Ingolf Cascorbi, Antje Herrmann, Ivar Roots, Michael Laule, Verena Stangl, and Karl Stangl Blood 2000 96: 2002-2003. [Full Text] [PDF] This article has been cited by other articles: C. Antoniades, D. Tousoulis, C. Vasiliadou, E. Stefanadi, K. Marinou, and C. Stefanadis Genetic Polymorphisms of Platelet Glycoprotein Ia and the Risk for Premature Myocardial Infarction: Effects on the Release of sCD40L During the Acute Phase of Premature Myocardial Infarction J. Am. Coll. Cardiol., May 16, 2006; 47(10): 1959 - 1966. [Abstract] [Full Text] [PDF] J. Mikkelsson, M. Perola, and P. J. Karhunen Genetics of Platelet Glycoprotein Receptors: Risk of Thrombotic Events and Pharmacogenetic Implications Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 113 - 125. [Abstract] [PDF] B. Nieswandt and S. P. Watson Platelet-collagen interaction: is GPVI the central receptor? Blood, July 15, 2003; 102(2): 449 - 461. [Abstract] [Full Text] [PDF] T. J. Kunicki The Influence of Platelet Collagen Receptor Polymorphisms in Hemostasis and Thrombotic Disease Arterioscler. Thromb. Vasc. Biol., January 1, 2002; 22(1): 14 - 20. [Abstract] [Full Text] [PDF] W. R. P. Agema, J. W. Jukema, S. N. Pimstone, and J. J. P. Kastelein Genetic aspects of restenosis after percutaneous coronary interventions;towards more tailored therapy Eur. Heart J., November 2, 2001; 22(22): 2058 - 2074. [PDF] C. Meisel, I. Cascorbi, A. Herrmann, I. Roots, M. Laule, V. Stangl, and K. Stangl The platelet glycoprotein Ia C807T polymorphism as risk factor for coronary catheter interventions. Blood, September 1, 2000; 96(5): 2002 - 2003. [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by von Beckerath, N. Articles by Kastrati, A. Search for Related Content PubMed PubMed Citation Articles by von Beckerath, N. Articles by Kastrati, A. Related Collections Hemostasis, Thrombosis, and Vascular Biology Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020